Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Alendronic acid effervescent tablets (Binosto®) - SMC 1136/16 - Formulary Group decision will be published by  4th May 2016. (Indication: for the treatment of postmenopausal osteoporosis).

Camellia sinensis (green tea) leaf extract (Catephen®) - SMC 1133/16 - In progress. (Indication: for the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years).

Enzalutamide (Xtandi®) - SMC 1066/15 - Formulary Group decision will be published by  4th May 2016. (Indication: for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated).

Everolimus (Afinitor®) - SMC 872/13 - Formulary Group decision will be published by  4th May 2016. (Indication: for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor).

Gefitinib (Iressa®) - SMC 615/10 - Formulary Group decision will be published by 4th May 2016. (Indication: for the treatment of previously untreated adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK)).

Guanfacine (Intuniv®) - SMC 1123/16 - Formulary Group decision will be published by 4th May 2016. (Indication: for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective).

Horse Antigen - FG1 390/15 - In progress. (Indication: for the treatment of aplastic anaemia.) 

Isavuconazole (Cresemba®) - SMC 1129/16 - In progress.
(Indication : for the treatment of adults with: 
- invasive aspergillosis 
- mucormycosis in patients for whom amphotericin B is inappropriate).

Ivermectin (Soolantra®) - SMC 1104/15 - In progress. (Indication: for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients).

Lenalidomide (Revlimid®) - SMC 1096/15 - In progress (Indication: for the treatment of adult patients, who are unsuitable for thalidomide-containing regimens, with previously untreated multiple myeloma who are not eligible for transplant).

Pembrolizumab (Keytruda®) - SMC 1086/15 - In progress (Indication: as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab).

Zoledronic acid -Formulary Group decision will be published by 4th May 2016. (Indication: for the prevention of skeletal related events in adult patients with advanced malignancies involving bone).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END